HLA-A*0201 & B2M & HPV (TIHDIILECV)

HLA-A*0201 & B2M & HPV (TIHDIILECV) Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag & Avi Tag (1)
Marker
Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
HLV-H82E5	Human	HEK293	Biotinylated Human HLA-A*02:01&B2M&HPV (TIHDIILECV) Complex Protein (Monomer, MALS verified)				In den Warenkorb legen

Gesamtmenge1

Produktanfrage

HLA-A*0201 & B2M & HPV (TIHDIILECV) Molekülhintergrund

Human papillomavirus (HPV) is A kind of papillomavirus belonging to the milk polypoid virus family. It is a spherical D virus, which can cause the proliferation of squamous epithelium of human skin mucosa. HPV(human papillomavirus) for common warts, genital warts (condyloma acuminatum), and other symptoms. There are many types of human papillomavirus (HPV), with HPV 16 and 18 being high-risk types known to significantly increase the risk of cervical, vaginal and vulvar cancers in women and men. The Biotin human HLA-A*0201 HPV (TIHDIILECV) protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and TIHDIILECV peptide of the HPV.

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Ningetinib Tosylate	CT-053-PTSA; CT-053	Phase 2 Clinical	Hec Pharm Co Ltd	Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
Merestinib	5OGS5K699E; LY-2801653	Phase 2 Clinical	Eli Lilly And Company	Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung	Details
Do-2	Do-2	Phase 1 Clinical	DeuterOncology NV	Lung Neoplasms	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Crizotinib	PF-1066; PF-2341066; PF-02341066; PF-002341066	Approved	Pfizer Inc	赛可瑞, Xalkori	United States	Carcinoma, Non-Small-Cell Lung	Pf Prism Cv	2011-08-26	Urethral Neoplasms; Neoplasm Metastasis; Adenocarcinoma; Neurilemmoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Granuloma, Plasma Cell; Endometrial Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma; Ureteral Neoplasms; Solid tumours; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Neuroblastoma; Urinary Bladder Neoplasms; Myofibroma; Uveal melanoma; Multiple Myeloma; Neurofibromatosis 2; Neoplasms; Renal Insufficiency; Hematologic Neoplasms	Details